AL-LAD

1. 2026-10-19issueIssued emergency
2. 2026-10-19issueIssued info_card
3. 2026-10-19issueIssued notice
4. 2026-09-24srcPharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants
5. 2026-09-24srcReturn of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)
6. 2026-09-24srcReturn of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)
7. 2026-09-24srcReturn of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775)
8. 2026-09-24srcAnalytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LAD
9. 2026-09-24srcAnalytical profile of the lysergamide 1cP-AL-LAD and detection of impurities
10. 2026-09-24srcGenie in a blotter: A comparative study of LSD and LSD analogues' effects and user profile
11. 2026-09-24srcA Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD
12. 2026-09-24srcPharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA)
13. 2026-09-24srcPsychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey
14. 2026-09-24srcIn vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures
15. 2026-09-24srcCrystal Structure of an LSD-Bound Human Serotonin Receptor
16. 2026-09-24srcPharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD)
17. 2026-09-24srcPost-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis
18. 2026-09-24srcTolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
19. 2026-09-24srcSynthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives
20. 2026-09-24srcIdentification of 5-HT2A receptor signaling pathways associated with psychedelic potential
21. 2026-09-24srcNeuropsychological profiles of patients suffering from hallucinogen persisting perception disorder (HPPD): A comparative analysis with psychedelic-using and non-using controls
22. 2026-09-24srcAdverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD)
23. 2026-09-24srcSerotonin syndrome: is it a reason to avoid the use of tramadol with antidepressants?
24. 2026-09-24srcLegal highs: staying on top of the flood of novel psychoactive substances
25. 2026-09-24srcPsychedelics and the human receptorome
26. 2026-09-24srcHallucinogens
27. 2026-09-24srcLSD and structural analogs: pharmacological evaluation at D1 dopamine receptors
28. 2026-09-24srcStudies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds
29. 2026-09-24srcTiHKAL: The Continuation
30. 2026-09-24srcAL-LAD legal status — Wikipedia, PsychonautWiki, AddictionResource
31. 2026-09-04issueIssued emergency
32. 2026-09-04issueIssued info_card
33. 2026-09-04issueIssued notice
34. 2026-06-04proposal29 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
35. 2026-06-04publicationPublication — backfill
36. 2026-04-25revisionRevision 1
37. 2026-04-25absenceSearched ClinicalTrials.gov for "AL-LAD lysergamide" — no results
38. 2026-04-25genGeneration — pipeline-v5 · with 3 morepipeline-v5
39. 2026-04-25rungeneration run
40. 2026-04-24rungeneration run

The same entries, as forms: six forms.